Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Lister

Showing results (81-90 of 120) with videos related to

Pageof 12
Sort By:
Blood|June 5, 2008
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cellsDavid C Taussig, Farideh Miraki-Moud, Fernando Anjos-Afonso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activitySandra J Strauss, Lenushka Maharaj, Susan Hoare, et al.
Blood|November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaSteven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonistsLilian Alcaraz, Andrew Bailey, Elaine Cadogan, et al.
Communications Chemistry|April 9, 2025
Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent bindingPasquale A Morese, Ayaz Ahmad, Mathew P Martin, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2020
Development of autotaxin inhibitors: A series of tetrazole cinnamidesChristopher G Thomson, Darren Le Grand, Mark Dowling, et al.
Communications Chemistry|May 19, 2025
Author Correction: Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent bindingPasquale A Morese, Ayaz Ahmad, Mathew P Martin, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Pageof 12

Showing results (81-90 of 120) with videos related to

Sort By:
Pageof 12
Blood|June 5, 2008
Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cellsDavid C Taussig, Farideh Miraki-Moud, Fernando Anjos-Afonso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2006
Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activitySandra J Strauss, Lenushka Maharaj, Susan Hoare, et al.
Blood|November 19, 2008
Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemiaSteven P Treon, Andrew R Branagan, Leukothea Ioakimidis, et al.
The New England Journal of Medicine|April 23, 2015
Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphomaJohn Radford, Tim Illidge, Nicholas Counsell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2006
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphomaSandra J Strauss, Frank Morschhauser, Juergen Rech, et al.
Bioorganic & Medicinal Chemistry Letters|November 15, 2011
From libraries to candidate: the discovery of new ultra long-acting dibasic β₂-adrenoceptor agonistsLilian Alcaraz, Andrew Bailey, Elaine Cadogan, et al.
Communications Chemistry|April 9, 2025
Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent bindingPasquale A Morese, Ayaz Ahmad, Mathew P Martin, et al.
Bioorganic & Medicinal Chemistry Letters|November 7, 2020
Development of autotaxin inhibitors: A series of tetrazole cinnamidesChristopher G Thomson, Darren Le Grand, Mark Dowling, et al.
Communications Chemistry|May 19, 2025
Author Correction: Factors affecting irreversible inhibition of EGFR and influence of chirality on covalent bindingPasquale A Morese, Ayaz Ahmad, Mathew P Martin, et al.
Blood|July 2, 2008
CNS Hodgkin lymphomaElizabeth R Gerstner, Lauren E Abrey, David Schiff, et al.
Pageof 12